Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $71.31M
• Dividend Yield: N/A
• Average Volume (3M): 758.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: -39.62%
• EPS Growth: 6.83%
• Country: US
• Employees: 202
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 37,533,134
• 10 Day Avg. Volume: 423,832
• 30 Day Avg. Volume: 758,084
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.50
• Enterprise Value/Revenue: -3.17
• Enterprise Value/Gross Profit: -3.17
• Enterprise Value/Ebitda: 1.24
• 1Y Price Target: $4.50
• Price Target Upside: 141.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 42 Neutral
• Price Target: $2.00 ▲(7.53% Upside)

Metagenomi, Inc. faces significant financial and technical challenges, with ongoing losses and bearish stock momentum. However, recent corporate developments in gene editing and a strong cash position provide some positive outlook.

Positive Factors

Partnerships and Collaborations

Partnerships continue to progress with nomination of 1-2 DCs from the IONS collaboration expected, showing active collaboration efforts.

Pipeline Development

Additional internal and partnered programs are progressing, with preclinical proof of concept achieved in several areas, showcasing a broad development pipeline.

Research and Development

MGX highlighted NHP durability data from the hemophilia A program, demonstrating sustained FVIII activity in treated subjects, indicating promising results.

Negative Factors

Earnings

MGX reported a net loss per share that was worse than the consensus estimate.

Financial Performance

MGX reported a Q2 net loss of $19.9MM, pointing to financial challenges.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

How the Company Makes Money

Metagenomi, Inc. generates revenue through the development and commercialization of its proprietary gene editing technologies. The company engages in strategic partnerships and collaborations with pharmaceutical and biotechnology companies to co-develop and license its technology for therapeutic applications. These partnerships often involve milestone payments, licensing fees, and royalties based on the successful development and commercialization of gene therapies. Additionally, Metagenomi may receive funding from research grants and government programs aimed at advancing genetic research and innovation.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. shows strong revenue growth but faces profitability and cash flow challenges. The balance sheet indicates improving equity but requires careful monitoring of debt levels and liquidity.

Income Statement

Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.

Balance Sheet

The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.

Cash Flow

Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	33.77M	52.30M	44.76M	17.20M	243.00K
Gross Profit	33.77M	52.30M	40.55M	15.47M	-144.00K
EBITDA	-86.30M	-83.49M	-74.28M	-39.19M	-20.75M
Net Income	-87.12M	-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet
Total Assets	272.28M	324.60M	364.84M	414.49M	141.99M
Cash, Cash Equivalents and Short-Term Investments	204.99M	248.31M	271.18M	362.13M	108.15M
Total Debt	42.99M	45.78M	48.23M	18.57M	48.93M
Total Liabilities	76.45M	89.74M	500.43M	488.91M	174.54M
Stockholders Equity	195.83M	234.86M	-135.58M	271.68M	43.95M
Cash Flow
Free Cash Flow	-98.96M	-112.19M	-101.22M	15.75M	21.35M
Operating Cash Flow	-97.01M	-109.07M	-91.41M	29.72M	24.26M
Investing Cash Flow	63.41M	-88.16M	45.73M	-122.20M	-74.32M
Financing Cash Flow	-735.00K	84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.86
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 1.86 is below the 20-day moving average (MA) of 2.17, below the 50-day MA of 1.90, and below the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 26.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	56 Neutral	$6.72B	7.77	-9.67%	6.24%	14.98%	-4.62%
MGX	42 Neutral	$71.31M	―	-37.45%	―	-39.62%	6.83%
DOMH	―	$95.28M	―	-29.28%	―	―	―
IMAB	45 Neutral	$407.33M	―	-22.38%	―	-100.00%	72.51%
IOBT	43 Neutral	$84.33M	―	-212.51%	―	―	19.65%
ADAP	39 Underperform	$19.32M	―	-1341.37%	―	-53.61%	-93.14%
INZY	37 Underperform	$258.25M	―	-141.69%	―	―	-17.06%

Metagenomi, Inc. Corporate Events

Metagenomi Reports Strong Q2 2025 Financial Results

Metagenomi, Inc. reported its second quarter 2025 financial results and business updates, highlighting significant advancements in its gene editing technologies. The company presented three abstracts at the American Society of Gene & Cell Therapy, showcasing early proof-of-concept data for its gene editing technologies, and announced a strong cash position of $205 million, expected to support operations into 2027. Metagenomi continues to advance its MGX-001 program for Hemophilia A and its collaboration with Ionis in cardiometabolic indications, while also enhancing its board with the appointment of Laurence Reid, Ph.D. The company is focused on operational efficiency and investment in its pipeline and AI-driven metagenomics platform.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Metagenomi, Inc. Holds Annual Stockholders Meeting

On June 10, 2025, Metagenomi, Inc. held its annual meeting of stockholders virtually, where a quorum was established with 18,765,221 shares present or represented by proxy. During the meeting, stockholders elected Willard H. Dere, M.D. as a Class I Director until 2028 and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.